There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
Moclobemide is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A[3]. Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders. The effective therapeutic dose range for moclobemide in most acute phase trials was 300 to 600 mg, divided in 2 to 3 doses. Cases of refractory depression might improve with a combination of moclobemide with other antidepressants, such as clomipramine or a SSRI (selective serotonin reuptake inhibitors)[4]. In humans, moclobemide is rapidly absorbed after a single oral administration and maximum concentration in plasma is reached within an hour. In the case of moclobemide, increase in the level of serotonin is the most pronounced. Moclobemide administration also leads to increased monoamine receptor stimulation, reversal of reserpine induced behavioral effects, selective depression of REM sleep, down regulation of beta-adrenoceptors and increases in plasma prolactin and growth hormone levels. It reduces scopolamine-induced performance decrement and alcohol induced performance deficit which suggest a neuroprotective role[5]. Long-term treatment with moclobemide causes gynecomastia in rats, which is reversible[6]. Morever, moclobemide overdose in combination with a serotonergic agent (even in normal therapeutic doses) can cause severe serotonin toxicity[7].
Moclobemide/吗氯贝胺 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Rat hippocampal neural stem cells
200 μM
Cells did not survive
Br J Pharmacol. 2006 Jul;148(5):563-4.
Rat hippocampal neural stem cells
50 μM
Promoted differentiation of neural stem cells into serotoninergic neuron-like cells, increased cell survival, upregulated expression of antiapoptotic genes Bcl-2 and Bcl-XL
Br J Pharmacol. 2006 Jul;148(5):563-4.
Neural stem cells (NSCs)
50 μM
24, 48, 72 hours
Moclobemide increases the viability and proliferation of NSCs, upregulates the gene expressions of Bcl-2 and Bcl-xL, and prevents FasL-induced apoptosis
Br J Pharmacol. 2006 Jul;148(5):587-98.
Moclobemide/吗氯贝胺 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Albino Swiss mice
Forced swim test (FST) and tail suspension test (TST)
Intraperitoneal injection
1.5 mg/kg
Single dose, 60 min before
To evaluate the impact of CB receptor ligands on the antidepressant activity of Moclobemide. Results showed that AM251 (0.25 mg/kg) potentiated the antidepressant effects of Moclobemide.
Pharmacol Rep. 2020 Dec;72(6):1562-1572
Swiss Albino mice
Tail suspension test and forced swimming test
Intraperitoneal injection
30 mg/kg
Three doses within 24 hours (t = 0, 18, 24 hours)
Evaluation of antidepressant activity, results showed Moclobemide as a standard drug exhibited antidepressant potential at 30 mg/kg dose
Mol Divers. 2022 Dec;26(6):3157-3172
Mice
Acute pain model
Intraperitoneal injection
69.1 mg/kg
Single administration
To evaluate the antinociceptive effect of Moclobemide in a mouse model of acute pain and its interaction with the opioid system. Results showed that Moclobemide produced a dose-dependent antinociceptive effect, but this effect was not significantly inhibited by naloxone, indicating no opioid involvement in its antinociceptive effect.
Canada, Ontario
... 展开 >>
Research Imaging Centre, Centre for Addiction and Mental Health
Recruiting
Toronto, Ontario, Canada, M5T 1R8
Principal Investigator: Jeffrey H Meyer, MD, PhD 收起 <<
Canada, Ontario
... 展开 >>
Research Imaging Centre, Centre for Addiction and Mental Health
Recruiting
Toronto, Ontario, Canada, M5T 1R8
Principal Investigator: Jeffrey H Meyer, MD, PhD 收起 <<
France
... 展开 >> University Hospital of Besançon- Jean Minjoz
Recruiting
Besançon, France, 25030
Contact: Pierre VANDEL pierre.vandel@univ-fcomte.fr
University Hospital of Caen
Recruiting
Caen, France, 14000
Contact: Sonia DOLLFUS dollfus-s@chu-caen.fr
University Hospital of Lille
Recruiting
Lille, France, 59000
Contact: Jean ROCHE Jean.ROCHE@CHRU-LILLE.FR
University Hospital of Nice
Recruiting
Nice, France, 06000
Contact: Philippe ROBERT robert.p@chu-nice.fr
Sainte-Anne Hospital
Recruiting
Paris, France, 75014
Contact: Thierry GALLARDA T.GALLARDA@ch-sainte-anne.fr
Le Rouvray Hospital
Recruiting
Sotteville lès Rouen, France, 76300
Contact: Marie DESBORDES marie.desbordes@ch-lerouvray.fr
University Hospital of Strasbourg - HUS
Recruiting
Strasbourg, France, 67098
Contact: Frédéric BLANC frederic.blanc@chru-strasbourg.fr
University Hospital of Toulouse - Purpan
Recruiting
Toulouse, France, 31059
Contact: Christophe ARBUS arbus.c@chu-toulouse.fr
University Hospital of Tours
Recruiting
Tours, France, 37000
Contact: Vincent CAMUS vincent.camus@univ-tours.fr 收起 <<
United States, North Carolina
... 展开 >>
Duke Center for Smoking Cessation
Charlotte, North Carolina, United States, 28210
Duke Center forSmoking Cessation
Durham, North Carolina, United States, 27705
Duke Center for Smoking Cessation
Winston-Salem, North Carolina, United States, 27103 收起 <<
搜索
HazMat Fee +
